Immutep - ADR opened lower at $3.30, compared with its previous close of $3.56. In the last trading session, the stock traded between $3.30 and $3.95. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Immutep - ADR is now worth
$ 91.61
Resulting in a loss of
$ 8.39 (8.39%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.09 (+2.42%)
Day High
$3.95
Day Low
$3.30
Day Open
$3.30
Prev Close
$3.56
Volume
60,668
1W Return
23.93%
1M Return
0.44%
3M Return
832.48%
6M Return
722.84%
1Y Return
104.83%
Fundamentals
Market Cap ($ Mn)
27
PE Ratio
-
PB Ratio
0.85
PEG Ratio
-
ROE
-36.45%
ROCE
-39.35%
EPS (TTM)
-
Investment Returns
1 Week
23.93%
1 Month
0.44%
3 Months
832.48%
6 Months
722.84%
9 Months
30.68%
Financials
Quarterly
All values in $ Mn
0.0
Sep 24
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
Updates
11Nov
Immutep reports 81% disease-free survival in sarcoma trial
Immutep Limited reported 81.1% 12-month disease-free survival in the EFTISARC-NEO Phase II trial. Local recurrence-free survival reached 94.1% and distant metastasis-free survival hit 86.2%. The trial met its primary endpoint with 51.5% median tumour hyalinisation, exceeding the 35% target. Data supports further registrationally relevant trials for efti combined with pembrolizumab and radiotherapy.
2 days ago
14Oct
Monash University receives A$652,248 ARC grant for Immutep LAG-3 research
Monash University received A$652,248 from the Australian Research Council for LAG-3 research. The grant is awarded under the competitive ARC Linkage Projects scheme for a three-year period. Funding supports Immutep Limited's collaboration on novel immunotherapies for cancer and autoimmune diseases.
